Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.
Annie HawtonElizabeth GoodwinKate BoddyJennifer FreemanSarah ThomasJeremy ChatawayColin GreenPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2020)
We conclude by highlighting methodological and policy developments which should aid addressing these limitations.